;28(Suppl 1):179-217.
18. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M,
et al. Results of a double-blind, placebo-controlled study to assess the
safety of intramuscular injection of hepatocyte growth factor plasmid to
improve limb perfusion in patients with critical limb ischemia. Circulation 2008;118:58-65.
19. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S,
Masaki H, et al. Therapeutic angiogenesis for patients with limb
ischaemia by autologous transplantation of bone-marrow cells: a pilot
study and a randomised controlled trial. Lancet 2002;360:427-35.
20. Benoit E, O’Donnell TF, Iafrati MD, Ascher E, Bandyk DF,
Hallett JW, et al. The role of amputation as an outcome measure in
cellular therapy for critical limb ischemia: implications for clinical trial
design. JTM 2011;9:165.
21. Powell RJ. Update on clinical trials evaluating the effect of biologic
therapy in patients with critical limb ischemia. J Vasc Surg 2012;56:264-6.
22. Taylor SM, York JW, Cull DL, Kalbaugh CA, Cass AL, Langan EM.
Clinical success using patient-oriented outcome measures after lower
extremity bypass and endovascular intervention for ischemic tissue loss.
J Vasc Surg 2009;50:534-41.
23. Armstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic
foot ulcers and vascular insufﬁciency: our population has changed, but
our methods have not. J Diabetes Sci Technol 2011;52:1591-5.
24. Bradbury AW, Ruckley CV, Fowkes FGR, Forbes JF, Gillespie I,
Adam DJ, et al. Bypass versus Angioplasty in Severe Ischem